GeneFab, LLC acquired Rights, title and interest in certain of the assets from Senti Biosciences, Inc. for $37.8 million.
August 09, 2023
Share
GeneFab, LLC entered into a framework agreement to acquire Rights, title and interest in certain of the assets from Senti Biosciences, Inc. (NasdaqGM:SNTI) for $37.8 million on August 7, 2023. 50% of the Cash Consideration was paid at closing and the remainder will become due and payable by GeneFab on or before December 31, 2024, unless the Company elects to receive up to two early payments of a portion of the Deferred Consideration prior to December 31, 2024, in which case the remaining portion of the unpaid Deferred Consideration will become due and payable on December 31, 2025. Rights related to the Alameda Facility, GeneFab also intends to extend offers of employment to approximately 46 of the Company's employees currently employed in its research and development, manufacturing, and quality functions. Philip Lee, Ph.D., Co-Founder and Chief Technology Officer of Senti Bio will depart from his position at Senti Bio and assume the role of Chief Executive Officer of GeneFab. Cooley LLP and Goodwin Procter LLP are serving as legal advisors to Senti Bio. Morrison & Foerster LLP is serving as legal advisor to Celadon Partners and GeneFab.
GeneFab, LLC completed the acquisition of Rights, title and interest in certain of the assets from Senti Biosciences, Inc. (NasdaqGM:SNTI) on August 7, 2023.
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
SENTI BIOSCIENCES, INC. 
